Abstract:There is an increasing body of knowledge regarding how COVID-19 may be associated with ocular disease of varying severity and duration. This article discusses the literature on the ocular manifestations associated with COVID-19, including appraisal of the current evidence, suggested mechanisms of action, associated comorbidities and risk factors, timing from initial infection to diagnosis and clinical red flags. The current literature primarily comprises case reports and case series which inevitably lack control groups and evidence to support causality. However, these early data have prompted the development of larger population-based and laboratory studies that are emerging. As new data become available, a better appraisal of the true effects of COVID-19 on the eye will be possible. While the COVID-19 pandemic was officially declared no longer a "global health emergency" by the World Health Organization (WHO) in May 2023, case numbers continue to rise. Reinfection with different variants is predicted to lead to a growing cumulative burden of disease, particularly as more chronic, multi-organ sequelae become apparent with potentially significant ocular implications. COVID-19 ocular manifestations are postulated to be due to three main mechanisms: firstly, there is a dysregulated immune response to the initial infection linked to inflammatory eye disease; secondly, patients with COVID-19 have a greater tendency towards a hypercoagulable state, leading to prothrombotic events; thirdly, patients with severe COVID-19 requiring hospitalisation and are immunosuppressed due to administered corticosteroids or comorbidities such as diabetes mellitus are at an increased risk of secondary infections, including endophthalmitis and rhino-orbital-mucormycosis. Reported ophthalmic associations with COVID-19, therefore, include a range of conditions such as conjunctivitis, scleritis, uveitis, endogenous endophthalmitis, corneal graft rejection, retinal artery and vein occlusion, non-arteritic ischaemic optic neuropathy, glaucoma, neurological and orbital sequelae. With the need to consider telemedicine consultation in view of COVID-19's infectivity, understanding the range of ocular conditions that may present during or following infection is essential to ensure patients are appropriately triaged, with prompt in-person ocular examination for management of potentially sight-threatening and life-threatening diseases.

Ocular manifestations of West Nile virus

Systemic and Ocular Manifestations of Arboviral Infections: A Review

[Ocular manifestations of viral diseases]

Unique Magnetic Resonance Imaging Findings in Opsoclonus-Myoclonus Syndrome Secondary to the West Nile Virus

Ocular manifestations of COVID-19

Ocular manifestations associated with chikungunya

West Nile virus meningoencephalitis and cytokines analysis: review and case report

Clinical and Diagnostic Features of West Nile Virus Neuroinvasive Disease in New York City

COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19

[Opsoclonus-myoclonus syndrome associated with West Nile virus]

Ophthalmologic manifestations in the posterior segment of the eye after coronavirus infection

Neuroinvasive West Nile Virus Infection in Immunosuppressed and Immunocompetent Adults

Catastrophic Case of West Nile Virus Rhombencephalitis in AIDS

Ocular manifestations of cytomegalovirus in immunocompetent hosts

West Nile Virus in a Changing Climate: epidemiology, pathology, advances in diagnosis and treatment, vaccine designing and control strategies, emerging public health challenges - a comprehensive review

Bilateral multifocal chorioretinitis as the only presentation of acute West Nile virus infection: a case report

Ophthalmic manifestations in the COVID-19 clinical spectrum

West Nile Virus Neuroinvasive Disease in Patients Treated with anti-CD20 Therapies

Ophthalmic Manifestations in COVID-19 Patients, a Review

Manifestations of COVID-19 in the posterior eye segment - Up-to-date

Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis.